ReviewAnnals of hematology2025
Lactic acidosis as the initial presentation of lymphoma: A case report and integrated analysis of clinical characteristics and prognostic factors.
Review in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Persistent lactic acidosis in ALK-positive anaplastic large cell lymphoma: a case report and literature review.Frontiers in oncology · 2026Article
- Metabolic reprogramming in tumor-associated cells of hematologic malignancies: mechanisms, crosstalk networks, and therapeutic implications in the tumor microenvironment.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Type B lactic acidosis (LA), a rare yet fatal complication of lymphoma with poor prognosis, remains poorly characterized due to reliance on isolated case reports. To systematically delineate clinical characteristics and prognostic determinants in newly diagnosed lymphoma patients presenting with LA as the initial presentation, we conducted an integrated analysis synthesizing unpublished institutional cases with systematically identified cases from PubMed, Web of Science, and hospital databases. Demographic, clinical, laboratory, imaging, histopathological, and therapeutic intervention data were extracted. Prognostic correlates were evaluated using univariate and multivariate logistic regression, with predictive accuracy validated through receiver operating characteristic (ROC) curves. Among the 53 patients analyzed, the predominant manifestations included general malaise and gastrointestinal symptoms (62.3% each), with infrequent superficial lymph node enlargement (15.1%). Key biochemical abnormalities included hyperlactatemia (peak lactate: 15.89 ± 7.82 mmol/L) and elevated lactate dehydrogenase (60.4%). Imaging revealed lymph node enlargement (41.5%) and hepatic abnormalities (39.6%). Non-survivors were significantly older (P = 0.007), had a higher incidence of B-symptoms (P = 0.032), and were less likely to receive chemotherapy (P < 0.001). Chemotherapy emerged as the sole independent predictor of survival (multivariate odds ratio [OR] = 0.020; 95% confidence interval [CI]: 0.002-0.211; P = 0.001), validated by ROC curve analysis (sensitivity 92.0%, specificity 95.5%). This integrated analysis of a case and literature review underscores that LA signifies aggressive lymphoma with frequent advanced-stage disease. Although advanced age and B-symptoms predicted mortality, chemotherapy was the sole independent survival predictor in multivariate analysis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.